Literature DB >> 24769592

Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer.

Catherine M Bender1, Amanda L Gentry2, Adam M Brufsky3, Frances E Casillo4, Susan M Cohen4, Meredith M Dailey4, Heidi S Donovan4, Jacqueline Dunbar-Jacob5, Rachel C Jankowitz6, Margaret Q Rosenzweig7, Paula R Sherwood8, Susan M Sereika9.   

Abstract

PURPOSE/
OBJECTIVES: To comprehensively assess the patient and illness or treatment factors that may predict nonadherence to adjuvant endocrine therapy and to explore whether an interaction occurs between these factors in women with breast cancer.
DESIGN: Repeated-measures design.
SETTING: The Outpatient Services of the Women's Cancer Program at the University of Pittsburgh Cancer Institute and participants' homes. SAMPLE: 91 women with early-stage breast cancer who received endocrine therapy.
METHODS: Adherence was assessed continuously for the first 18 months of endocrine therapy. Patient and illness or treatment factors were assessed at four time points (Time 1 to Time 4). Time 1 (baseline) was within two weeks prior to the initiation of endocrine therapy. Times 2-4 occurred at six-month intervals, as many as 18 months after Time 1. MAIN RESEARCH VARIABLES: Adherence, patient factors, and illness or treatment factors.
FINDINGS: Adherence to endocrine therapy declined significantly during the first 18 months of treatment in women with breast cancer. The presence of negative mood and symptoms before starting treatment predicted nonadherence to endocrine therapy over time. Perceptions of financial hardship, symptoms, disease stage, and more complex medication regimens intensified the effect of negative mood on adherence over time.
CONCLUSIONS: Women with breast cancer may be at risk for nonadherence to prescribed endocrine therapy if they experience depression or anxiety and symptoms prior to initiating therapy. IMPLICATIONS FOR NURSING: Oncology nurses should be alert to women with breast cancer who are depressed or anxious or who are experiencing symptoms. Management of negative mood and symptoms may result in better adherence.

Entities:  

Keywords:  adherence; breast cancer; financial hardship; mood; symptoms

Mesh:

Substances:

Year:  2014        PMID: 24769592      PMCID: PMC4090095          DOI: 10.1188/14.ONF.274-285

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  44 in total

1.  The psychological sense of economic hardship: measurement models, validity, and cross-ethnic equivalence for urban families.

Authors:  M Barrera; H Caples; J Y Tein
Journal:  Am J Community Psychol       Date:  2001-06

2.  Tamoxifen non-compliance: does it matter?

Authors:  Vedang Murthy; Geeta Bharia; Rajiv Sarin
Journal:  Lancet Oncol       Date:  2002-11       Impact factor: 41.316

3.  Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women.

Authors:  S Demissie; R A Silliman; T L Lash
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

4.  Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer.

Authors:  Rebecca A Silliman; Edward Guadagnoli; William Rakowski; Mary Beth Landrum; Timothy L Lash; Robert Wolf; Aliza Fink; Patricia A Ganz; Jerry Gurwitz; Catherine Borbas; Vincent Mor
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

Review 5.  Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients.

Authors:  A D Valentine; C A Meyers
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

6.  Patient-by-treatment context interaction in chronic disease: a conceptual framework for the study of patient adherence.

Authors:  A J Christensen
Journal:  Psychosom Med       Date:  2000 May-Jun       Impact factor: 4.312

Review 7.  Patient adherence to treatment: three decades of research. A comprehensive review.

Authors:  E Vermeire; H Hearnshaw; P Van Royen; J Denekens
Journal:  J Clin Pharm Ther       Date:  2001-10       Impact factor: 2.512

8.  First-degree relatives of breast-cancer patients: cognitive perceptions, coping, and adherence to breast self-examination.

Authors:  Miri Cohen
Journal:  Behav Med       Date:  2002       Impact factor: 3.104

9.  Pretreatment predictors of short-term nonadherence to oral hormonal therapy for women with breast cancer.

Authors:  Karen E Wickersham; Susan M Sereika; Catherine M Bender
Journal:  Nurs Res       Date:  2013 Jul-Aug       Impact factor: 2.381

10.  Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Authors:  Gottfried Konecny; Giovanni Pauletti; Mark Pegram; Michael Untch; Sugandha Dandekar; Zuleima Aguilar; Cindy Wilson; Hong-Mei Rong; Ingo Bauerfeind; Margret Felber; He-Jing Wang; Malgorzata Beryt; Ram Seshadri; Herrmann Hepp; Dennis J Slamon
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

View more
  48 in total

1.  Talking About My Care: Detecting Mentions of Hormonal Therapy Adherence Behavior in an Online Breast Cancer Community.

Authors:  Zhijun Yin; Wei Xie; Bradley A Malin
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

2.  Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.

Authors:  G J van Londen; Heidi S Donovan; Ellen B Beckjord; Alexandra L Cardy; Dana H Bovbjerg; Nancy E Davidson; Jennifer Q Morse; Galen E Switzer; Irma M Verdonck-de Leeuw; Mary Amanda Dew
Journal:  Oncol Nurs Forum       Date:  2014-11-01       Impact factor: 2.172

3.  Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy.

Authors:  E M Quinn; C Fleming; M J O'Sullivan
Journal:  Ir J Med Sci       Date:  2015-05-14       Impact factor: 1.568

Review 4.  A Systematic Review of Adherence to Oral Antineoplastic Therapies.

Authors:  Joseph A Greer; Nicole Amoyal; Lauren Nisotel; Joel N Fishbein; James MacDonald; Jamie Stagl; Inga Lennes; Jennifer S Temel; Steven A Safren; William F Pirl
Journal:  Oncologist       Date:  2016-02-26

5.  Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer.

Authors:  John D Merriman; Susan M Sereika; Adam M Brufsky; Priscilla F McAuliffe; Kandace P McGuire; Jamie S Myers; Mary L Phillips; Christopher M Ryan; Amanda L Gentry; Lindsay D Jones; Catherine M Bender
Journal:  Psychooncology       Date:  2015-10-20       Impact factor: 3.894

6.  Symptoms and QOL in breast cancer patients receiving hormone therapy in Japan.

Authors:  Yukiko Iioka; Takako Iwata; Hideko Yamauchi
Journal:  Breast Cancer       Date:  2019-07-11       Impact factor: 4.239

Review 7.  Using Information Technology in the Assessment and Monitoring of Geriatric Oncology Patients.

Authors:  Kah Poh Loh; Colin McHugh; Supriya G Mohile; Karen Mustian; Marie Flannery; Heidi Klepin; Rebecca Schnall; Eva Culakova; Erika Ramsdale
Journal:  Curr Oncol Rep       Date:  2018-03-06       Impact factor: 5.075

8.  Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.

Authors:  Hira Mian; Mark Fiala; Tanya M Wildes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-10-09

9.  Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.

Authors:  Moriah J Brier; Dianne L Chambless; Robert Gross; Jinbo Chen; Jun J Mao
Journal:  Cancer       Date:  2016-08-29       Impact factor: 6.860

10.  "Winging It": How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment.

Authors:  Eden R Brauer; Patricia A Ganz; Huibrie C Pieters
Journal:  J Oncol Pract       Date:  2016-09-30       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.